115 filings
6-K
CVAC
CureVac N.V.
24 Apr 24
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
4:30pm
6-K
CVAC
CureVac N.V.
24 Apr 24
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
4:20pm
6-K
CVAC
CureVac N.V.
24 Apr 24
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
4:15pm
6-K
CVAC
CureVac N.V.
16 Apr 24
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
4:15pm
6-K
CVAC
CureVac N.V.
4 Apr 24
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
4:15pm
6-K
zxjryq1 ibepujd
17 Jan 24
CureVac CEO Alexander Zehnder Acquires Common Shares of Company Stock
9:02am
6-K
4biaj
5 Jan 24
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development
4:15pm
6-K
zsq4v2bmz7ofql844
19 Dec 23
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
4:30pm
6-K
5ua mwr05gvbs1qroy6x
14 Nov 23
Current report (foreign)
4:15pm
6-K
7w3vhnhb29p 6xhu5w3m
14 Nov 23
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update
4:15pm
6-K
l9rvfuutv3
1 Nov 23
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSK
4:45pm
6-K
p9bizr rb8xs
28 Sep 23
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in Germany
4:30pm
6-K
x4hmfa5 y89
12 Sep 23
Current report (foreign)
4:30pm
6-K
xcv1u
17 Aug 23
Current report (foreign)
4:30pm
6-K
np3x4
17 Aug 23
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business Update
4:30pm
6-K
793 4ew2cep811o
1 Aug 23
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
4:15pm
6-K
ilk0vipdz fl
14 Jul 23
CureVac Announces Update to the Management Team
4:01pm
6-K
nb90f 7juvd3g5gyw
13 Jul 23
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
4:01pm
6-K
sq1yxrz8w n0oopwkts
22 Jun 23
Current report (foreign)
4:01pm
6-K
iusfg
20 Jun 23
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
4:45pm